Evidence map›Paper›PMID 41442108›Full record

SynthesisCardiovascular intervention and therapeutics2026

Limus- versus paclitaxel-coated balloons for coronary in-stent restenosis: meta-analysis of randomized controlled trials.

Mohammadreza Babaei, Parisa Fallahtafti, Sina Rashedi, Somayyeh Barati, Ehsan Khalilipur, Ata Firouzi, Mehdi H Shishehbor, Parham Sadeghipour

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohammadreza BabaeiVascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Institute, Vali-Asr Ave, Tehran, 1995614331, Iran.
Parisa FallahtaftiCardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Sina RashediThrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Somayyeh BaratiVascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Institute, Vali-Asr Ave, Tehran, 1995614331, Iran.
Ehsan KhalilipurCardiovascular Intervention Research Center, Rajaie Cardiovascular Institute, Tehran, Iran.
Ata FirouziCardiovascular Intervention Research Center, Rajaie Cardiovascular Institute, Tehran, Iran.
Mehdi H ShishehborUniversity Hospitals Harrington Heart and Vascular Institute, Cleveland, OH, USA.
Parham SadeghipourVascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Institute, Vali-Asr Ave, Tehran, 1995614331, Iran. psadeghipour@hotmail.com.ORCID http://orcid.org/0000-0001-9602-0513

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-coated balloons (DCB) are increasingly utilized for treating in-stent restenosis (ISR), yet the comparative efficacy of limus-coated balloons (LCBs) versus paclitaxel-coated balloons (PCBs) remains uncertain. The aim of this study is to compare the clinical and angiographic outcomes of LCB versus PCBs in treating ISR. We searched PubMed, Embase, and ClinicalTrials.gov through July 2025 for RCTs comparing LCBs versus PCBs in patients with ISR. The primary outcome was late lumen loss (LLL). Secondary outcomes included percentage diameter stenosis (%DS), minimal lumen diameter (MLD), and binary restenosis at 6-12 months and target lesion revascularization (TLR), target lesion failure (TLF), target vessel myocardial infarction, cardiac death, and stent thrombosis at 12 months. Mean differences (MDs) were calculated for continuous outcomes and relative risks (RRs) for binary outcomes. Six RCTs with 968 patients (512 LCB, 456 PCB) showed statistical non-inferiority for LLL with an MD of 0.06 mm (-0.07 to 0.18, P for non-inferiority < 0.001, I

Indexed as

Angioplasty, Balloon, CoronaryCoated Materials, BiocompatibleCoronary RestenosisDrug-Eluting StentsPaclitaxelHumansRandomized Controlled Trials as TopicCoated Materials, BiocompatiblePaclitaxelBiolimusDrug-coated balloonIn-stent restenosisMeta-analysisPaclitaxelSirolimus

Identifiers

PMID41442108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.